Drug Type Antibody drug conjugate (ADC) |
Synonyms SG2918 |
Target |
Action inhibitors, stimulants |
Mechanism LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | China | 29 Nov 2023 | |
| Liver Cancer | Phase 1 | China | 29 Nov 2023 |






